Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 in

NCT05303129 is registered in ClinicalTrials.gov with Centre Francois Baclesse as lead sponsor.

NCT NCT05303129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05303129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 in
Lead sponsor
Centre Francois Baclesse
Phase
Not applicable
Overall status
Completed
Start date
May 27, 2022
Completion date
December 17, 2024
Enrollment
165 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastatic breast cancer